Streetbeat News

ELV

Elevance Health Inc.

https://www.elevancehealth.com

Industry

Medical - Healthcare Plans

Elevance Health Inc. operates as a health benefits company. It supports consumers, families, and communities across the entire care journey connecting to the care, support, and resources to lead healthier lives. It serves approximately 118 million people through a portfolio of medical, digital, pharmacy, behavioral, clinical, and care solutions. The company was formerly known as Anthem, Inc. and changed its name to Elevance Health Inc. in June 2022. Elevance Health Inc. was founded in 1944 and is headquartered in Indianapolis, Indiana.

Open

405.00

Mkt cap

93B

Volume

2.6M

High

408.58

P/E Ratio

14.58

52-wk high

567.26

Low

398.69

Div yield

0.02

52-wk low

397.98

Elevance Health reported Q2 2024 adjusted EPS of $10.12, beating the estimate of $10.01. Sales were $43.223 billion, also surpassing the estimate of $43.054 billion.

Portfolio Pulse from Benzinga Newsdesk

July 17, 2024 | 10:01 am

Shares of health insurers are trading higher in sympathy with UnitedHealth, which gained following strong Q2 earnings.

Portfolio Pulse from Benzinga Newsdesk

July 16, 2024 | 2:27 pm

Elevance Health shares are trading higher after Truist Securities maintained a Buy rating on the stock and raised its price target from $600 to $620.

Portfolio Pulse from Benzinga Newsdesk

July 16, 2024 | 2:12 pm

Elevance Health (NYSE:ELV) has been analyzed by 15 financial analysts, showing a range of bullish to somewhat bullish sentiments. The average 12-month price target has increased by 3.2% to $612.93. Recent analyst actions include several rating raises and maintained overweight ratings, indicating positive sentiment towards the stock.

Portfolio Pulse from Benzinga Insights

July 15, 2024 | 4:01 pm

Truist Securities analyst David Macdonald maintains a Buy rating on Elevance Health (NYSE:ELV) and raises the price target from $600 to $620.

Portfolio Pulse from Benzinga Newsdesk

July 15, 2024 | 2:02 pm

Morgan Stanley has initiated coverage on Elevance Health Inc (NYSE:ELV) with an Overweight rating and a price target of $643, citing its diversified portfolio and undervaluation. Despite challenges in Medicare Advantage, Elevance's resilience and growth potential in segments like Pharmacy Benefit Management and Carelon Services are highlighted. Elevance's shares have risen 13.3% year-to-date, trading at a P/E ratio of 13.6 times, slightly below its diversified peers.

Portfolio Pulse from Vandana Singh

June 24, 2024 | 5:45 pm

Elevance Health (NYSE:ELV) has been analyzed by 16 analysts over the past three months, showing a range of perspectives from bullish to somewhat bullish. The average 12-month price target has increased to $605.69, with a high estimate of $649.00 and a low estimate of $557.00. Recent analyst actions include several rating raises and price target adjustments, indicating a generally positive outlook.

Portfolio Pulse from Benzinga Insights

June 24, 2024 | 12:01 pm

Morgan Stanley has initiated coverage on Elevance Health (NYSE:ELV) with an Overweight rating and set a price target of $643.

Portfolio Pulse from Benzinga Newsdesk

June 24, 2024 | 9:39 am

Elevance Health (NYSE:ELV) has outperformed the market over the past 10 years with an average annual return of 17.18%, surpassing the market by 6.3% annually. A $100 investment in ELV 10 years ago would now be worth $491.68.

Portfolio Pulse from Benzinga Insights

June 20, 2024 | 3:00 pm

Elevance Health's executive announced that the company's Medicare earnings are growing this year, and the company is making money, not losing it, in Medicare. This statement was made at a Goldman Sachs conference.

Portfolio Pulse from Benzinga Newsdesk

June 12, 2024 | 5:32 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.